Psychiatric safety of bimekizumab versus interleukin-23 inhibitors in psoriasis: A real-world TriNetX cohort study

Authors

• Christina Tolete, Department of Dermatology, George Washington University, School of Medicine and Health Sciences, Washington, District of Columbia.
• Adam Friedman, Department of Dermatology, George Washington University, School of Medicine and Health Sciences, Washington, District of Columbia.
• Joaquin Calderon, Department of Dermatology, George Washington University, School of Medicine and Health Sciences, Washington, District of Columbia.
• Leonardo Tjahjono, Department of Dermatology, George Washington University, School of Medicine and Health Sciences, Washington, District of Columbia.

Document Type

Journal Article

Publication Date

4-1-2026

Journal

JAAD international

Volume

25

DOI

10.1016/j.jdin.2026.02.006

Keywords

IL-17 inhibitor; IL-23 inhibitor; bimekizumab; depression; mental health; psoriasis; suicidal ideation; suicide

APA Citation

Tolete, Christina; Friedman, Adam; Calderon, Joaquin; and Tjahjono, Leonardo, "Psychiatric safety of bimekizumab versus interleukin-23 inhibitors in psoriasis: A real-world TriNetX cohort study" (2026). GW Authored Works. Paper 9152.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/9152

Department

Dermatology